RPL21P133: A Promising Drug Target / Biomarker (G100271391)

Target Name: RPL21P133

NCBI ID: G100271391

RPL21P133

Other Name(s): RPL21_63_1815 | Ribosomal protein L21 pseudogene 133 | ribosomal protein L21 pseudogene 133

RPL21P133: A Promising Drug Target / Biomarker

The protein RPL21P133 is a key regulator of the Replication Protein Complex (RPC), which is responsible for ensuring the accurate and efficient replication of DNA in eukaryotic cells. The RPC is a complex of proteins that includes the protein RPL21, which is the core component of the RPC, and several other proteins that work together to ensure the proper formation and function of the complex.

The RPL21P133 protein is a key component of the RPC and is involved in the regulation of DNA replication. It is a 21-kDa protein that contains a unique N-terminal domain that is important for its functions in the RPC. The N-terminal domain is composed of a single amino acid, which is a critical residue that is involved in the formation of a hydrophobic cluster. This cluster is thought to play a role in the stability and stability of the RPC, as well as the regulation of DNA replication.

The RPL21P133 protein is a potential drug target or biomarker because of its involvement in the regulation of DNA replication, which is a crucial process for the survival and growth of most organisms. In addition, the RPL21P133 protein is also known to be a key regulator of the cell cycle, which is the process by which cells divide and grow. This suggests that it may also be involved in the regulation of cell growth and the development of cancer.

The RPL21P133 protein is also of interest because of its unique structure and its location in the cell. It is a single protein that contains a unique N-terminal domain that is located at the center of the RPC. This suggests that it plays a critical role in the regulation of the RPC as a whole, as well as in the regulation of DNA replication specifically.

Expression and Regulation

The RPL21P133 protein is expressed in most eukaryotic cells and is involved in the regulation of DNA replication. It is expressed in the cytoplasm and in the nuclear envelope, which is the outer layer of the cell's nucleus. It is also found in the RPC, which is a complex of proteins that includes the protein RPL21, as well as several other proteins that work together to ensure the proper formation and function of the complex.

The RPL21P133 protein is regulated by several different factors, including the amount of DNA replication that is needed, the level of competition for DNA replication, and the availability of resources such as energy and nutrients. These factors can affect the stability and stability of the RPC, as well as the efficiency of DNA replication.

The RPL21P133 protein is also regulated by several different signaling pathways, including the TOR signaling pathway and the PI3K/Akt signaling pathway. These signaling pathways are involved in the regulation of cell growth, cell cycle progression, and other processes that are important for the survival and growth of most organisms.

Drugs that Interact with RPL21P133

The RPL21P133 protein is a potential drug target or biomarker because of its involvement in the regulation of DNA replication and the cell cycle. Drugs that interact with the RPL21P133 protein may be useful in treating a variety of diseases, including cancer, neurodegenerative diseases, and diseases that are caused by disruptions in the cell cycle.

One class of drugs that may interact with the RPL21P133 protein is those that are used to treat cancer. Many anti-cancer drugs work by inhibiting the activity of the RPL21P133 protein, which is involved in the regulation of DNA replication and the cell cycle. These drugs may be useful in treating a variety of different types of cancer, including breast

Protein Name: Ribosomal Protein L21 Pseudogene 133

The "RPL21P133 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL21P133 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets